ACM
VIVO

Americafirst Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Americafirst Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18,286
Closed -$377K – 272
2016
Q1 		$377K Buy
+18,286
New +$360K 0.24% 126

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Americafirst Capital Management's VIVO Position: Q2 2016 in Review

Americafirst Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2016, closing a stake of 18,286 shares — an estimated $377K sold.

Americafirst Capital Management first reported a position in VIVO in Q1 2016 and held it in 1 quarter. The position peaked at $377K in Q1 2016. 180 funds tracked by Wall St. Rank hold VIVO as of Q2 2016.

  • Americafirst Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2016 after selling out during the quarter.
  • Americafirst Capital Management sold 18,286 Meridian Bioscience Inc shares in Q2 2016, an estimated $377K.
  • Americafirst Capital Management first reported a position in Meridian Bioscience Inc in Q1 2016 and held it in 1 quarter.
  • Americafirst Capital Management's Meridian Bioscience Inc position peaked at $377K in Q1 2016.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2016.

Based on Americafirst Capital Management's 13F filing for Q2 2016, filed 18 Jul 2016.